JP2017516785A5 - - Google Patents

Download PDF

Info

Publication number
JP2017516785A5
JP2017516785A5 JP2016569636A JP2016569636A JP2017516785A5 JP 2017516785 A5 JP2017516785 A5 JP 2017516785A5 JP 2016569636 A JP2016569636 A JP 2016569636A JP 2016569636 A JP2016569636 A JP 2016569636A JP 2017516785 A5 JP2017516785 A5 JP 2017516785A5
Authority
JP
Japan
Prior art keywords
disease
cancer
salt according
autoimmune
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016569636A
Other languages
English (en)
Japanese (ja)
Other versions
JP6987501B2 (ja
JP2017516785A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/053940 external-priority patent/WO2015181728A1/en
Publication of JP2017516785A publication Critical patent/JP2017516785A/ja
Publication of JP2017516785A5 publication Critical patent/JP2017516785A5/ja
Application granted granted Critical
Publication of JP6987501B2 publication Critical patent/JP6987501B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016569636A 2014-05-27 2015-05-26 医薬製剤用pi3kデルタ選択的抑制剤の改良形態 Expired - Fee Related JP6987501B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN2596/CHE/2014 2014-05-27
IN2597/CHE/2014 2014-05-27
IN2596CH2014 2014-05-27
IN2597CH2014 2014-05-27
PCT/IB2015/053940 WO2015181728A1 (en) 2014-05-27 2015-05-26 Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020088147A Division JP2020122022A (ja) 2014-05-27 2020-05-20 医薬製剤用pi3kデルタ選択的抑制剤の改良形態

Publications (3)

Publication Number Publication Date
JP2017516785A JP2017516785A (ja) 2017-06-22
JP2017516785A5 true JP2017516785A5 (cg-RX-API-DMAC7.html) 2017-08-03
JP6987501B2 JP6987501B2 (ja) 2022-01-05

Family

ID=53499042

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016569636A Expired - Fee Related JP6987501B2 (ja) 2014-05-27 2015-05-26 医薬製剤用pi3kデルタ選択的抑制剤の改良形態
JP2020088147A Pending JP2020122022A (ja) 2014-05-27 2020-05-20 医薬製剤用pi3kデルタ選択的抑制剤の改良形態
JP2022062937A Pending JP2022082680A (ja) 2014-05-27 2022-04-05 医薬製剤用pi3kデルタ選択的抑制剤の改良形態

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020088147A Pending JP2020122022A (ja) 2014-05-27 2020-05-20 医薬製剤用pi3kデルタ選択的抑制剤の改良形態
JP2022062937A Pending JP2022082680A (ja) 2014-05-27 2022-04-05 医薬製剤用pi3kデルタ選択的抑制剤の改良形態

Country Status (22)

Country Link
US (4) US9969740B2 (cg-RX-API-DMAC7.html)
EP (2) EP3149000B1 (cg-RX-API-DMAC7.html)
JP (3) JP6987501B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170007480A (cg-RX-API-DMAC7.html)
CN (2) CN111635406A (cg-RX-API-DMAC7.html)
AU (1) AU2015265542B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016027674A2 (cg-RX-API-DMAC7.html)
CA (1) CA2949932C (cg-RX-API-DMAC7.html)
CY (1) CY1124316T1 (cg-RX-API-DMAC7.html)
DK (1) DK3149000T3 (cg-RX-API-DMAC7.html)
EA (1) EA032506B1 (cg-RX-API-DMAC7.html)
ES (1) ES2880999T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211151T1 (cg-RX-API-DMAC7.html)
HU (1) HUE054916T2 (cg-RX-API-DMAC7.html)
IL (1) IL249058B2 (cg-RX-API-DMAC7.html)
LT (1) LT3149000T (cg-RX-API-DMAC7.html)
PL (1) PL3149000T3 (cg-RX-API-DMAC7.html)
PT (1) PT3149000T (cg-RX-API-DMAC7.html)
RS (1) RS62136B1 (cg-RX-API-DMAC7.html)
SI (1) SI3149000T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100532T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015181728A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3149000T (lt) * 2014-05-27 2021-09-10 Rhizen Pharmaceuticals S.A. Pi3k delta selektyvaus inhibitoriaus kristalinės tozilato druskos panaudojimas farmacinėse kompozicijose
AU2017268839A1 (en) 2016-05-27 2018-11-29 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat B-cell proliferative disorders
JP2019526595A (ja) 2016-09-09 2019-09-19 ティージー セラピューティクス,インコーポレイテッド 血液癌を治療するための抗cd20抗体、pi3キナーゼ−デルタ阻害剤および抗pd−1抗体または抗pd−l1抗体の組み合わせ
WO2021009509A1 (en) 2019-07-15 2021-01-21 Johnson Matthey Public Limited Company Amorphous umbralisib monotosylate
WO2022104150A1 (en) 2020-11-12 2022-05-19 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3029041T1 (sl) * 2000-04-25 2020-08-31 Icos Corporation Inhibitorji humane delta fosfatidil-inozitol 3-kinaze
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
EP2355828B1 (en) 2008-11-13 2018-05-30 Gilead Calistoga LLC Therapies for hematologic malignancies
EP2411391A1 (en) 2009-03-24 2012-02-01 Gilead Calistoga LLC Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
CA2759724A1 (en) 2009-04-20 2010-10-28 Calistoga Pharmaceuticals, Inc. Methods of treatment for solid tumors
ES2647416T3 (es) 2012-07-04 2017-12-21 Rhizen Pharmaceuticals S.A. Inhibidores de PI3K delta selectivos
LT3149000T (lt) * 2014-05-27 2021-09-10 Rhizen Pharmaceuticals S.A. Pi3k delta selektyvaus inhibitoriaus kristalinės tozilato druskos panaudojimas farmacinėse kompozicijose

Similar Documents

Publication Publication Date Title
JP2017516785A5 (cg-RX-API-DMAC7.html)
JP2019163290A5 (cg-RX-API-DMAC7.html)
JP7749642B2 (ja) Retroviridaeウイルス感染の処置において有用な治療用化合物を調製するための方法および中間体
HRP20171610T1 (hr) Selektivni inhibitori pi3k delta
JP2020537657A5 (cg-RX-API-DMAC7.html)
JP2017505808A5 (cg-RX-API-DMAC7.html)
HRP20211151T1 (hr) Kristalinska tosilatna sol pi3k delta selektivnog inhibitora za uporabu u farmaceutskim formulacijama
JP2017501234A5 (cg-RX-API-DMAC7.html)
JP2018511634A5 (cg-RX-API-DMAC7.html)
JP7629580B1 (ja) ベンゾピリミジン化合物及びその使用
JP2022520236A (ja) 化合物、組成物、及び、方法
JP2019518071A5 (cg-RX-API-DMAC7.html)
JP2019515952A5 (cg-RX-API-DMAC7.html)
JP2020066629A5 (cg-RX-API-DMAC7.html)
JP2013525433A5 (cg-RX-API-DMAC7.html)
JP2018520205A5 (cg-RX-API-DMAC7.html)
JP2020519654A5 (cg-RX-API-DMAC7.html)
JP2016128501A5 (cg-RX-API-DMAC7.html)
JP2016537346A5 (cg-RX-API-DMAC7.html)
ES2588170T3 (es) 5-[(3,3,3-Trifluoro-2-hidroxi-1-arilpropil)amino]-1H-quinolin-2-onas, procedimiento para su producción y su uso como agentes antiinflamatorios
JP2013502396A5 (cg-RX-API-DMAC7.html)
TW201609679A (zh) 磷脂酸肌醇-3-激酶抑制劑的製造方法
CN119110801A (zh) 选择性抑制parp1的氟代喹喔啉酮衍生物
JP2010529986A5 (cg-RX-API-DMAC7.html)
JP2013525448A5 (cg-RX-API-DMAC7.html)